CardioMind Launches First In Human Trial Of Small Vessel, Drug Eluting Stent

CardioMind, Inc., a developer of stents for small, difficult-to-treat blood vessels, announced that it has begun a First-in-Human clinical trial of its drug-eluting stent. The CARE II trial, as it is called, began in February at St. Vincent's Hospital in Melbourne, Australia, and, so far, has led to successful implantations in 12 patients. With a .